Lung Cancer Clinical Trial
Official title:
A Personalised Prehabilitation Model for Patients Undergoing Chemotherapy, Radiotherapy and/or Immunotherapy Treatment for Lung Cancer: A Feasibility Pilot Study
Background The term 'prehabilitation' refers to a period of time before treatment and often includes diet, exercise and/or wellbeing plans to help patients through their cancer treatment. Prehabilitation has shown to benefit patients having surgery, but there is little research into its use in the oncological setting. The United Kingdom sees more deaths from lung cancer than any other cancer. 70-80% of lung cancer patients receive oncological treatment. Treatment side effects can have a significant impact on quality of life. Personalised prehabilitation can take into account the challenges patients face, helping patients through treatment. Aim To see if a personalised plan of diet, exercise and emotional support can be used in practice for patients having chemotherapy, radiotherapy and/or immunotherapy treatment for lung cancer. Methods The study will involve lung cancer patients from Imperial College Healthcare NHS Trust who are: - Over the age of 18 years old - Have not had previous lung cancer surgery and - Are about to start chemotherapy, radiotherapy or immunotherapy treatment The prehabilitation interventions will be based upon patient need and readiness, assessed using: - A series of questionnaires - An assessment of walking - A measure of grip strength These will be done prior to, at week three and at week six of a patient's oncological treatment regime. Personalised goals will be agreed at each stage. Throughout treatment, patients will be asked to keep a daily diary to record their symptoms, appetite, mobility and mood. The diary will also be used to monitor goal adherence. Public involvement Patients will be part of a study advisory group, helping with research design and dissemination e.g. with the presentation of findings to the lung cancer support group. Dissemination All patients will receive a written summary of findings. Results will be shared in a scientific journal and presented at relevant conferences. Patients will not be identifiable.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | September 1, 2023 |
Est. primary completion date | June 30, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 99 Years |
Eligibility | Inclusion Criteria: - Adults (aged = 18 years) diagnosed with lung cancer - Able to give informed consent - Due to embark on a chemotherapy, radiotherapy and/or immunotherapy treatment pathway Exclusion Criteria: - On a surgical pathway - Have had previous lung cancer surgery - Unable to understand verbal or written English - Unable to give informed consent |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Imperial College Healthcare NHS Trust | London |
Lead Sponsor | Collaborator |
---|---|
Imperial College Healthcare NHS Trust |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Feasible eligibility, recruitment and refusal rates | Use of descriptive statistics - number approached, eligible, recruited, refused | Immediately after week six of oncological treatment | |
Primary | How many participants do not participate in the personalised prehabilitation programme and explore the reasons why | Use of descriptive statistics, field notes taken during the Lung Cancer Multi-Disciplinary Team (LCMDT) and participant discussion | Immediately after week six of oncological treatment | |
Primary | Number of participants who are not suitable for the personalised prehabilitation programme and the reasons why | Use of descriptive statistics and field notes taken during the LCMDT, where discussions of eligibility will take place | Immediately after week six of oncological treatment | |
Primary | Attrition rate throughout the personalised prehabilitation programme | Use of descriptive statistics - number who drop out and at what stage | Immediately after week six of oncological treatment | |
Primary | Number of participants who adhere to the goals set for the personalised prehabilitation interventions | Adherence to goals set measured through participant discussion at the weekly telephone consultations | Immediately after week six of oncological treatment | |
Primary | Barriers and facilitators to adherence and intervention fidelity | Use of a daily diary - symptom log, discussions had with participants during the weekly telephone consultations, short free text questionnaire at the end of the study, analysed thematically | Immediately after week six of oncological treatment | |
Primary | Evaluation of participant acceptability of the emotion thermometer questionnaire used for the personalised prehabilitation programme | Completion rates, discussions had with participants during the weekly telephone consultations, short free text questionnaire at the end of the study, analysed thematically | Immediately after week six of oncological treatment | |
Primary | Evaluation of participant acceptability of the modified Godin leisure time exercise questionnaire used for the personalised prehabilitation programme | Completion rates, discussions had with participants during the weekly telephone consultations, short free text questionnaire at the end of the study, analysed thematically | Immediately after week six of oncological treatment | |
Primary | Evaluation of participant acceptability of the patient generated subjective global assessment questionnaire used for the personalised prehabilitation programme | Completion rates, discussions had with participants during the weekly telephone consultations, short free text questionnaire at the end of the study, analysed thematically | Immediately after week six of oncological treatment | |
Primary | Evaluation of participant acceptability of the patient activation measure questionnaire used for the personalised prehabilitation programme | Completion rates, discussions had with participants during the weekly telephone consultations, short free text questionnaire at the end of the study, analysed thematically | Immediately after week six of oncological treatment | |
Primary | Evaluation of participant acceptability of the cancer behaviour inventory questionnaire used for the personalised prehabilitation programme | Completion rates, discussions had with participants during the weekly telephone consultations, short free text questionnaire at the end of the study, analysed thematically | Immediately after week six of oncological treatment | |
Primary | Evaluation of participant acceptability of the patient generated index used for the personalised prehabilitation programme | Completion rates, discussions had with participants during the weekly telephone consultations, short free text questionnaire at the end of the study, analysed thematically | Immediately after week six of oncological treatment | |
Primary | Evaluation of participant acceptability of measuring body weight in kilograms for the personalised prehabilitation progamme | Completion rates, discussions had with participants during the weekly telephone consultations, short free text questionnaire at the end of the study, analysed thematically | Immediately after week six of oncological treatment | |
Primary | Evaluation of participant acceptability of measuring functional capacity by the distance covered in meters using the six minute walk test as part of the personalised prehabilitation programme | Completion rates, discussions had with participants during the weekly telephone consultations, short free text questionnaire at the end of the study, analysed thematically | Immediately after week six of oncological treatment | |
Primary | Evaluation of participant acceptability of measuring grip strength in kilograms using a handgrip dynamometer as part of the personalised prehabilitation programme | Completion rates, discussions had with participants during the weekly telephone consultations, short free text questionnaire at the end of the study, analysed thematically | Immediately after week six of oncological treatment | |
Primary | Evaluation of contextual or implementation factors which may influence acceptability of the intervention/s | Use of a daily diary - symptom log, discussions had with participants during the weekly telephone consultations; participant reflection, participant needs and priorities, short free text questionnaire at the end of the study, analysed thematically | Immediately after week six of oncological treatment | |
Primary | Evaluation of contextual or implementation factors which may influence effectiveness of the intervention/s | Use of a daily diary - symptom log, discussions had with participants during the weekly telephone consultations; participant reflection, participant needs and priorities, short free text questionnaire at the end of the study, analysed thematically | Immediately after week six of oncological treatment | |
Primary | The 'prehabilitation window' (length of time between diagnosis and the start of treatment) | Use of descriptive statistics - date of diagnosis, date of start of treatment, date of start and finish of prehabilitation | Immediately after week six of oncological treatment | |
Primary | The extent to which the prehabilitation programme has had an impact on psychological wellbeing | Use of the emotional thermometer questionnaire which will be used to assess psychological wellbeing - change between baseline and follow up, daily diary - symptom log, discussions had with participants during the weekly telephone consultations, short free text questionnaire at the end of the study, analysed thematically | Immediately after week six of oncological treatment | |
Primary | The extent to which the prehabilitation programme has had an impact on nutrition | Use of the Patient Generated Subjective Global Assessment (PG-SGA) tool which will be used to assess nutritional status - change between baseline and follow up, daily diary - symptom log, discussions had with participants during the weekly telephone consultations, short free text questionnaire at the end of the study, analysed thematically | Immediately after week six of oncological treatment | |
Primary | The extent to which the prehabilitation programme has had an impact on physical activity | Use of the Modified Godin leisure time exercise questionnaire which will be used to assess physical activity - change between baseline and follow up, daily diary - symptom log, discussions had with participants during the weekly telephone consultations, short free text questionnaire at the end of the study, analysed thematically | Immediately after week six of oncological treatment | |
Primary | Number of participants who require universal, targeted and specialist intervention | Use of questionnaires to assess level of need and readiness and descriptive statistics | Immediately after week six of oncological treatment | |
Secondary | Quality of life assessed using the European Organisation for Research and Treatment of Cancer (EORTC) QLQC30 questionnaire | Incidence of change between baseline and immediately after treatment assessed by any differences in the EORTC questionnaire | Baseline; pre-treatment, during treatment and immediately after treatment | |
Secondary | Quality of life assessed using the EuroQOL Group EQ-5D-5L questionnaire | Incidence of change between baseline and immediately after treatment assessed by any differences in the EQ-5D-5L questionnaire | Baseline; pre-treatment, during treatment and immediately after treatment | |
Secondary | Patient experience | Assessed via a short free text questionnaire. Patients will be able to openly give written feedback on their experience and offer any comments or suggestions | Immediately after week six of oncological treatment | |
Secondary | Functional capacity | Assessed by patients undertaking a six minute walk test | Baseline; pre-treatment, during treatment and immediately after treatment | |
Secondary | Handgrip strength | Assessed using a handgrip dynamometer to measure grip strength | Baseline; pre-treatment, during treatment and immediately after treatment |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03918538 -
A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors
|
N/A | |
Recruiting |
NCT05078918 -
Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors
|
N/A | |
Active, not recruiting |
NCT04548830 -
Safety of Lung Cryobiopsy in People With Cancer
|
Phase 2 | |
Completed |
NCT04633850 -
Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
|
||
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05583916 -
Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Not yet recruiting |
NCT06376253 -
A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers
|
Phase 1 | |
Recruiting |
NCT05898594 -
Lung Cancer Screening in High-risk Black Women
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03575793 -
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Terminated |
NCT01624090 -
Mithramycin for Lung, Esophagus, and Other Chest Cancers
|
Phase 2 | |
Terminated |
NCT03275688 -
NanoSpectrometer Biomarker Discovery and Confirmation Study
|
||
Not yet recruiting |
NCT04931420 -
Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels
|
Phase 2 | |
Recruiting |
NCT06052449 -
Assessing Social Determinants of Health to Increase Cancer Screening
|
N/A | |
Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
Not yet recruiting |
NCT06017271 -
Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
|
||
Recruiting |
NCT05787522 -
Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk
|